Using Urine Samples to Identify Lung Cancer
This study evaluate the use of an animal biosensor platform to identify non-small cell lung cancer.
Inclusion Criteria
- * Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC ** Note: Single, monolateral nodule of at least 50% solid composition visible on a chest CT scan that is suspicious for a primary neoplasm as confirmed by an official MSK radiologist read * Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC * Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and/or PET scan criteria
Exclusion Criteria
- * Aged < 18 years * Lack of available results from low-dose CT * Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year * Pregnant (for women) * Taking drugs that affect the immune system * Chronic disease related to the immune system * Missing clinical data (i.e., current clinical staging)
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06033248.
Locations matching your search criteria
United States
New Jersey
Basking Ridge
Middletown
Montvale
New York
Commack
New York
Uniondale
West Harrison
PRIMARY OBJECTIVES:
I. To determine the ability of the ABP to detect the presence or absence of NSCLC-specific VOCs in urine samples from patients with histologically proven NSCLC (stages I, II, and IIIA) and subjects without NSCLC. (Phase I)
II. To determine the ability of the ABP to detect NSCLC-specific VOCs in urine samples from patients with suspected but undiagnosed NSCLC (stages I, II, and IIIA). (Phase II)
OUTLINE: This is an observational study.
Participants undergo urine sample collection and have medical records reviewed on study.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorGaetano Rocco
- Primary ID23-111
- Secondary IDsNCI-2023-07166
- ClinicalTrials.gov IDNCT06033248